- Kincell Bio Inc. has signed a memorandum of understanding with Duke University School of Medicine to advance cell and gene therapy research and scalable manufacturing solutions.
- The collaboration includes joint program support, evaluation of emerging technologies such as AI and machine learning, and translational research initiatives.
Kincell Bio Inc., a cell therapy CDMO, has announced a memorandum of understanding with Duke University School of Medicine. The partnership aims to accelerate innovation in cell and gene therapy, strengthen translational pathways, and support scalable and efficient manufacturing of advanced biologics.
A joint steering committee, co-chaired by Bruce Thompson, Ph.D., CTO at Kincell Bio, and Beth Shaz, M.D., deputy director of Duke’s Marcus Center for Cellular Cures (MC3), will oversee collaboration initiatives. These include program referrals and cross-support for clinical trial design, donor screening, regulatory submissions, and both clinical and commercial-scale development.
The collaboration will also focus on emerging technologies, evaluating artificial intelligence and machine learning applications in process optimisation, predictive analytics, and clinical data integration. Translational research support will include co-development of enabling tools, joint grant applications, and academic–industry educational forums.
“This collaboration reflects our shared commitment to building an integrated biotech ecosystem in North Carolina and beyond,” said Thompson. “We look forward to accelerating the path from discovery to patient impact.”
“We want to bring innovative therapies closer to the patients who need them,” added Shaz. “Integrating tools like artificial intelligence and machine learning into our research workflows allows us to advance translational science and create new pathways for faculty innovations to achieve clinical impact and improve patient outcomes.”
